Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Phil Cheng

Has grant

Bioinformatician

University Hospital of Geneva

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Recent Grants

Grant: Close

Innate and acquired resistance mechanisms to melanoma targeted therapy

Open Date: 2021-12-01

Close Date: 2022-12-01

Grant: Close

Single cell RNAseq analysis of melanoma tumors before and after anti-PD1 therapy

Open Date: 2017-12-01

Close Date:

Grant: Close

Uncovering novel resistance mechanisms to BRAF and MEK inhibition by integrative RNAseq and targeted panel sequencing

Open Date: 2017-09-01

Close Date:

Grant: Close

The role of PKC signaling in melanoma targeted therapy resistance

Open Date: 2015-07-01

Close Date:

Grant: Close

Data mining The Cancer Genome Atlas

Open Date: 2015-02-01

Close Date: 2015-02-01

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (16)

Qun Zeng

University of Geneva

SWITZERLAND

View details

Lukas Sommer

Professor

University of Zurich

SWITZERLAND

View details

Salome Stierli

Senior scientist/Junior Principal Investigator

University of Zurich

SWITZERLAND

View details

Paweł Teterycz

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Thomas Biedermann

SWITZERLAND

View details

Mitchell Levesque

SWITZERLAND

View details

Ossia M Eichhoff

Senior Scientist

University Hospital of Zurich

SWITZERLAND

View details

Agnes S. Klar

Group Leader and Deputy Head

SWITZERLAND

View details

Richard Chahwan

University of Zurich

SWITZERLAND

View details

Mara Cenerenti

University of Oxford

UNITED KINGDOM

View details

Ramon Staeger

University Hospital of Zurich

SWITZERLAND

View details

Katherine M Aird

Professor

The Wistar Institute

UNITED STATES

View details

Michael O. Hottiger

University of Zurich

SWITZERLAND

View details

stephanie hugues

Vice-Dean for Careers, Research Support and Equality, Diversity and Inclusion

University of Geneva

SWITZERLAND

View details

Peter Schmid-Grendelmeier

Head Allergy Unit

Spital Davos AG

SWITZERLAND

View details

MONICA NANNI

Assist. Professional Researcher

UCSF

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Phil Cheng

Research Interests

Explore related searches

Recent Grants

Articles (20)

The Virtual Tissues foundation model resolves spatial proteomics across scales

Targeting ABL kinases overcomes melanoma immune evasion following resistance to MAPK inhibition

Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes

Positioning and reversible suppression of CCR7+dendritic cells in perivascular tumor niches shape cancer immunity

DNA Methyltransferase Inhibition Upregulates the Costimulatory Molecule ICAM-1 and the Immunogenic Phenotype of Melanoma Cells

Human Dermal Microvascular Arterial and Venous Blood Endothelial Cells and Their Use in Bioengineered Dermo‐Epidermal Skin Substitutes

Uncovering the Distinct Role of Phleum p 4 in Grass Pollen Allergy: Sensitization Patterns in 1963 Swiss Patients

Protein Kinase C Inhibition Overcomes Targeted Therapy Resistance in Cutaneous Melanoma

NLRP1 inflammasome activation in skin equivalents revealsmechanistic insights into the roles of keratinocytes in psoriasis

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients

Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy

TGFβ signaling sensitizes MEKi-resistant human melanoma to targeted therapy-induced apoptosis

Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance

Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe

A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study.

Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids.

Intrapatient heterogeneity and targeting microenvironment protection mechanisms in melanoma metastasis

Collaborators (16)

Qun Zeng

Lukas Sommer

Salome Stierli

Paweł Teterycz

Thomas Biedermann

Mitchell Levesque

Ossia M Eichhoff

Agnes S. Klar

Richard Chahwan

Mara Cenerenti

Ramon Staeger

Katherine M Aird

Michael O. Hottiger

stephanie hugues

Peter Schmid-Grendelmeier

MONICA NANNI

Make your next move.